(Q34132643)

31 July 2017

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy (English)

1 reference

31 July 2017

phase II clinical trial

0 references

0 references

1 reference

10

Patrick Y Wen

1 reference

31 July 2017

15

Timothy F Cloughesy

1 reference

31 July 2017

2

Lauren E Abrey

1 reference

31 July 2017

Jeffrey J Raizer

1

1 reference

31 July 2017

Andrew B Lassman

3

1 reference

31 July 2017

Susan M Chang

4

1 reference

31 July 2017

Kathleen R Lamborn

5

1 reference

31 July 2017

John G Kuhn

6

1 reference

31 July 2017

W K Alfred Yung

7

1 reference

31 July 2017

Mark R Gilbert

8

1 reference

31 July 2017

Kenneth A Aldape

9

1 reference

31 July 2017

Howard A Fine

11

1 reference

31 July 2017

Minesh Mehta

12

1 reference

31 July 2017

Lisa M Deangelis

13

1 reference

31 July 2017

Frank Lieberman

14

1 reference

31 July 2017

H Ian Robins

16

1 reference

31 July 2017

Janet Dancey

17

1 reference

31 July 2017

Michael D Prados

18

1 reference

31 July 2017

North American Brain Tumor Consortium

19

1 reference

31 July 2017

14 December 2009

1 reference

31 July 2017

1 reference

31 July 2017

12

1 reference

31 July 2017

95-103

1 reference

31 July 2017

1

1 reference

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

31 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Molecular pathogenesis of malignant gliomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Molecular changes during the genesis of human gliomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Chemotherapy for brain tumors--a new beginning.

28 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP015

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP015

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP015

Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP015

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP015

Gefitinib concentrations in human glioblastoma tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP015

Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP015

EGFR tyrosine kinase domain mutations in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP015

Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP015

The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Phase II trial of gefitinib in recurrent glioblastoma

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

Response criteria for phase II studies of supratentorial malignant glioma

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940554

28 October 2018

Identifiers

DOI

10.1093/NEUONC/NOP015

1 reference

31 July 2017

1 reference

31 July 2017

1 reference